First Opinion Gebra Cuyun Carter and Caitlin Kubler Address liquid biopsy disparities today to ensure equity in outcomes tomorrow
First Opinion Darrell Rigel Rising rates of skin cancer: The cost of FDA’s inaction on novel sunscreen products
First Opinion Juliana M. Reed PBMs aren’t opening access to lower-cost biosimilars. Reform is needed now
First Opinion Paul Hudson How artificial intelligence can bolster Europe’s competitive edge in biopharma
First Opinion Ezekiel J. Emanuel and John Connolly Mark Cuban’s company won’t fix drug costs, but it can still help rectify America’s drug shortages
First Opinion Jenny Rooke and Carolyn Bertozzi Leveraging scientific excellence to improve investment decisions
First Opinion P. Murali Doraiswamy and Lon S. Schneider Survey: Neurologists split on prescribing new Alzheimer’s treatments
First Opinion Onyeka T. Otugo and Adaira I. Landry Sonya Massey’s death: How to prevent more killings of defenseless Black women
First Opinion Melissa Batchelor and Diana J. Mason Without federal oversight, nursing homes will put profit ahead of care
First Opinion Emil D. Kakkis Sponsored genetic testing programs are under fire, further complicating life for people with rare diseases
First Opinion Thomas R. Insel Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it
Opinions+ Priya Baraniak STAT Plus: Cell donors are essential for new therapies. They need to be taken care of
First Opinion Richard Macary Fixing the reimbursement and coverage divide between ‘breakthrough’ drugs and medical devices
First Opinion Melissa Barber, Joseph S. Ross, and Reshma Ramachandran STAT Plus: To get a fair deal on Wegovy, buying Novo Nordisk might not be Medicare’s worst option
First Opinion Jonathan JK Stoltman and Mishka Terplan NIDA should beware of funding companies that violate people’s privacy
First Opinion Oni Blackstock and Whitney C. Irie The newest tool to prevent STIs is not available to everyone: A call for participatory and inclusive research
Letters to the editor Patrick Skerrett Readers respond to essays on philanthropy and nursing schools, opioid overdoses, and more
First Opinion David Gillum, Rebecca Moritz, and Gregory D. Koblentz The ‘Risky Research Review Act’ would do more harm than good
First Opinion Sarah E. Wakeman To overcome the overdose crisis, addiction treatment must be integrated into the health care system
First Opinion Spencer Phillips Hey and Michael S. Wilkes IRBs fail to assess trials’ scientific merit, putting participants at risk
First Opinion Podcast Patrick Skerrett Empathy should be the first response to people with vaccine injury, fears